2seventy bio, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has successfully completed a merger agreement with Bristol-Myers Squibb Company (NYSE:BMY). According to ...

2seventy bio, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has successfully completed a merger agreement with Bristol-Myers Squibb Company (NYSE:BMY). According to InvestingPro ...

Alexandria is a contrarian Buy opportunity with a 7.5% yield, robust fundamentals, & growth potential. See why ARE is Ideal ...

2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third ...

On Thursday, Citi analyst Samantha Semenkow revised the price target for 2Seventy Bio Inc. (NASDAQ:TSVT) shares to $9.00, a decrease from the previous $10.00 target, while upholding a Buy rating ...

In this comparison, we explore the analyst ratings and average 1-year price targets of Rigel Pharmaceuticals, 2seventy bio and Abeona Therapeutics, three prominent industry players, offering ...

The following analysis focuses on the analyst ratings and average 1-year price targets of Abeona Therapeutics, 2seventy bio and Vanda Pharmaceuticals, three prominent industry players, providing ...

The study – which tested Carvykti in patients with one to three lines of prior therapy – gives J&J an opportunity to leapfrog Bristol-Myers Squibb and 2Seventy bio's rival BCMA CAR-T therapy ...